Hirotaka Miyamoto

Dr. Hirotaka Miyamoto

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of Controlled Release
Verified
Journal Article
Open access
JPJian Qing Peng
Jian Qing Peng
SFShintaro Fumoto
Shintaro Fumoto
TSTadaharu Suga
Tadaharu Suga
HMHirotaka Miyamoto
Hirotaka Miyamoto
NKNaotaka Kuroda
Naotaka Kuroda
KNKoyo Nishida
Koyo Nishida
Synchronized bio-distribution of combination therapies has several merits such as synergistic effects and reduced side-effects. Co-delivery of a protein and small molecule drug using a single nanocarrier is challenging because they possess totally different characteristics. Herein, we report the development of sophisticated nanoparticles composed of lipids, calcium carbonate and RGD peptide ligands for the co-delivery of a protein and small molecule drug combination via a simple preparation method. A 'one-step' ethanol injection method was employed to prepare the highly organized nanoparticles. The nanoparticles exhibited a spherical shape with ca. 130 nm diameter, and clearly had an integrated lipid layer covering the periphery. As a ligand, an RGD-modified lipid was post-inserted into the nanoparticles, which was important to overcome the 'PEG dilemma'. The pH-sensitivity of the targeted nanoparticles contributed to the efficient intracellular co-delivery of a protein and drug combination in Colon26 tumor cells, and noticeably improved their accumulation in the tumor region of xenograft mice. Synchronized bio-distribution of the protein and drug was achieved, which was the foundation for the synergistic effects of the combination. The targeting capability of the nanoparticles along with their pH-sensitive drug release and the synchronized bio-distribution of their cargos led to the significant antitumor activity of the SOD and paclitaxel combination in mice. This study provides novel information for the design and preparation of functionalized nanoparticles for the delivery of a protein/drug combination in vivo.

3 June 2009 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SFShintaro Fumoto
Shintaro Fumoto
JNJunya Nishi
Junya Nishi
HIHiroki Ishii
Hiroki Ishii
XWXuan Wang
Xuan Wang
HMHirotaka Miyamoto
Hirotaka Miyamoto
KNKoyo Nishida
Koyo Nishida

2 May 2017 in Journal of Drug Targeting
Verified
Journal Article
Closed access
JPJianqing Peng
Jianqing Peng
SFShintaro Fumoto
Shintaro Fumoto
HMHirotaka Miyamoto
Hirotaka Miyamoto
YCYi Chen
Yi Chen
NKNaotaka Kuroda
Naotaka Kuroda
KNKoyo Nishida
Koyo Nishida
A doxorubicin (Dox) and curcumin (Cur) combination treatment regimen has been widely studied in pre-clinical research. However, the nanoparticles developed for this combination therapy require a consecutive drug loading process because of the different water-solubility of these drugs. This study provides a strategy for the “one-step” formation of nanoparticles encapsulating both Dox and Cur. We took advantage of polyacrylic acid (PAA) and calcium carbonate (CaCO3) to realise a high drug entrapment efficiency (EE) and pH-sensitive drug release using a simplified preparation method. Optimisation of lipid ratios and concentrations of CaCO3 was conducted. Under optimal conditions, the mean diameter of PEGylated lipid/PAA/CaCO3 nanoparticles with encapsulated Cur and Dox (LPCCD) was less than 100 nm. An obvious pH-sensitive release of both drugs was observed, with different Dox and Cur release rates. Successful co-delivery of Cur and Dox was achieved via LPCCD on HepG2 cells. LPCCD altered the bio-distribution of Dox and Cur in vivo and decreased Dox-induced cardiotoxicity. The current investigation has developed an efficient ternary system for co-delivery of Dox and Cur to tumours, using a “one-step” formation resulting in nanoparticles possessing remarkable pH-sensitive drug release behaviour, which may be valuable for further clinical studies and eventual clinical application.

15 June 2012 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SFShintaro Fumoto
Shintaro Fumoto
SNSayuri Nakajima
Sayuri Nakajima
TMToyoharu Mine
Toyoharu Mine
NYNaoki Yoshikawa
Naoki Yoshikawa
TKTakashi Kitahara
Takashi Kitahara
KNKoyo Nishida
Koyo Nishida

9 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SFShintaro Fumoto
Shintaro Fumoto
EKEriko Kinoshita
Eriko Kinoshita
KOKeisuke Ohta
Keisuke Ohta
KNKei-Ichiro Nakamura
Kei-Ichiro Nakamura
THTasuku Hirayama
Tasuku Hirayama
Koyo NishidaKoyo Nishida
Koyo Nishida
Visualizing biological events and states to resolve biological questions is challenging. Tissue clearing permits three-dimensional multicolor imaging. Here, we describe a pH-adjustable tissue clearing solution, Seebest (SEE Biological Events and States in Tissues), which preserves lipid ultrastructures at an electron microscopy level. Adoption of polyethylenimine was required for a wide pH range adjustment of the tissue clearing solution. The combination of polyethylenimine and urea had a good tissue clearing ability for multiple tissues within several hours. Blood vessels stained with lipophilic carbocyanine dyes were deeply visible using the solution. Adjusting the pH of the solution was important to maximize the fluorescent intensity and suppress dye leakage during tissue clearing. The spatial distribution of doxorubicin and oxidative stress were observable using the solution. Moreover, spatial distribution of liposomes in the liver was visualized. Hence, the Seebest solution provides pH-adjustable, rapid, sufficient tissue clearing, while preserving lipid ultrastructures, which is suitable for drug delivery system evaluations.

1 January 2013 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
NYNaoki Yoshikawa
Naoki Yoshikawa
SFShintaro Fumoto
Shintaro Fumoto
MNMikiro Nakashima
Mikiro Nakashima
KSKenta Shimokawa
Kenta Shimokawa
HMHirotaka Miyamoto
Hirotaka Miyamoto
KNKoyo Nishida
Koyo Nishida
We analyzed the effect of serum and fibronectin on pulmonary transgene expression after intravenous injection of cationic liposome–plasmid DNA (pDNA) complex (lipoplex) in mice. 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) methyl sulfate salt/cholesterol lipoplex was incubated with several serum components for 5 min at 37°C prior to injection. We analyzed pulmonary transgene expression and pulmonary accumulation of lipoplex. While interaction with serum did not decrease pulmonary transgene expression, interaction with heat-inactivated serum did decrease it. Moreover, interaction with fibronectin enhanced pulmonary transgene expression. Inhibition of the binding of fibronectin to integrin decreased pulmonary transgene expression after injection of untreated lipoplex. We found that pulmonary accumulation of lipoplex changed depending on the kind of interacting serum components after injection. Furthermore, interaction with fibronectin increased pulmonary accumulation of lipoplex. Interaction with serum was required for pulmonary gene transfer following intravenous injection of lipoplex. Fibronectin appears to be a particularly critical component. Furthermore, the binding of fibronectin interacting with lipoplex to integrin was an important mechanism for pulmonary transgene expression.